Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00215605
Status:
COMPLETED
Last Update Posted:
2013-02-27
First Post:
2005-09-20
Brief Title:
Study of XL184 Cabozantinib in Adults With Advanced Malignancies
Sponsor:
Exelixis
Organization:
Exelixis
Study Overview
Official Title:
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL184 Administered Orally to Subjects With Advanced Malignancies
Status:
COMPLETED
Status Verified Date:
2013-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the best and safest dose of XL184 administered orally XL184 is a new chemical entity that inhibits VEGFR2 MET and RET kinases implicated in tumor formation growth and migration To determine the highest safe dose subjects will receive different amounts of the drug The first group of subjects will receive the lowest dose of XL184 As long as no medically unacceptable side effects are noted the dose will be increased for the next group When the maximum tolerated dose MTD is reached at least 20 subjects with Medullary Thyroid Cancer MTC will be enrolled to evaluate the effect of XL184 in this population
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None